Abstract Number: 343 • 2019 ACR/ARP Annual Meeting
Emergency Department Length of Stay in Patients with Acute Gout
Background/Purpose: Emergency department (ED) visits for acute gout increased by approximately 20% between 2006 and 2014 in the United States. (1) Reducing ED length of stay…Abstract Number: 346 • 2019 ACR/ARP Annual Meeting
Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Background/Purpose: Gout is a very prevalent condition associated with many metabolic and cardiorenal comorbidities. A few studies have investigated the comorbidity subtypes of gout patients…Abstract Number: 348 • 2019 ACR/ARP Annual Meeting
Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry
Background/Purpose: A variety of newer gout therapies have been introduced in recent years, some with potential safety concerns. However, uptake of these therapies and associated…Abstract Number: 349 • 2019 ACR/ARP Annual Meeting
Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study
Background/Purpose: Carotid subclinical atherosclerosis is prevalent in patients with gout, although poorly predicted by cardiovascular risk assessment tools. Gout itself is deemed to contribute to…Abstract Number: 353 • 2019 ACR/ARP Annual Meeting
Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study
Background/Purpose: Several studies implicate gout and/or xanthine oxidase activity as risk factors for type 2 diabetes. However, no studies have directly evaluated the effect of…Abstract Number: 355 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol
Background/Purpose: Gout is the most common inflammatory arthritis and is particularly common among veterans. Recent studies, a randomized controlled trial (CARES, White et al. NEJM…Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…Abstract Number: 358 • 2019 ACR/ARP Annual Meeting
Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients
Background/Purpose: From 2006 to 2012, gout was the primary indication for ~0.2% of all emergency department visits for adults, as reported in the Nationwide Emergency…Abstract Number: 360 • 2019 ACR/ARP Annual Meeting
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Background/Purpose: Prophylaxis of acute gout flares when commencing urate lowering therapy is recommended by international guidelines. Whether this is a cost-effective intervention is currently unknown.…Abstract Number: 361 • 2019 ACR/ARP Annual Meeting
Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares
Background/Purpose: It is a common misconception that allopurinol should either be held or reduced during gout flares and renal insufficiency. However, current guidelines recommend the…Abstract Number: 362 • 2019 ACR/ARP Annual Meeting
Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries
Background/Purpose: Gout is frequently misdiagnosed and/or miscoded, making approaches to identifying eligible patients for observational and interventional studies more challenging. Ethnic and racial minorities are…Abstract Number: 363 • 2019 ACR/ARP Annual Meeting
Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout
Background/Purpose: Gout is the most common inflammatory arthritis in the US, and causes significant morbidity. Despite published guidelines and available effective treatment, management remains suboptimal,…Abstract Number: 365 • 2019 ACR/ARP Annual Meeting
Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data
Background/Purpose: Identifying pseudogout in large administrative datasets has been difficult due to lack of specific billing codes for this acute subtype of calcium pyrophosphate (CPP)…Abstract Number: 898 • 2019 ACR/ARP Annual Meeting
Ultrasound Demonstrates Rapid Reduction of Crystal Depositions During a Treat-to-target Approach in Gout Patients: Two-year Results from a Longitudinal, Observational Study (NOR-GOUT)
Background/Purpose: Ultrasound is sensitive for detecting depositions of uric monosodium urate (MSU) crystals and is included in the ACR/EULAR classification criteria for gout. The OMERACT…Abstract Number: 899 • 2019 ACR/ARP Annual Meeting
Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout
Background/Purpose: In small studies, cherries and cherry concentrate have been suggested to reduce serum urate and gout flares. The aims of this study were to…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »